GR1002097B - A process for providing a composition an analgesic in combination with a h1 or h2 receptor blocker proto n pump ihibitor or combination thereof - Google Patents

A process for providing a composition an analgesic in combination with a h1 or h2 receptor blocker proto n pump ihibitor or combination thereof

Info

Publication number
GR1002097B
GR1002097B GR900100786A GR900100786A GR1002097B GR 1002097 B GR1002097 B GR 1002097B GR 900100786 A GR900100786 A GR 900100786A GR 900100786 A GR900100786 A GR 900100786A GR 1002097 B GR1002097 B GR 1002097B
Authority
GR
Greece
Prior art keywords
combination
analgesic
ihibitor
proto
composition
Prior art date
Application number
GR900100786A
Other languages
English (en)
Other versions
GR900100786A (el
Inventor
William J Goldman
Thomas N Gates
Original Assignee
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23709269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR1002097(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc
Publication of GR900100786A publication Critical patent/GR900100786A/el
Publication of GR1002097B publication Critical patent/GR1002097B/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GR900100786A 1989-11-02 1990-11-01 A process for providing a composition an analgesic in combination with a h1 or h2 receptor blocker proto n pump ihibitor or combination thereof GR1002097B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43083789A 1989-11-02 1989-11-02

Publications (2)

Publication Number Publication Date
GR900100786A GR900100786A (el) 1992-04-17
GR1002097B true GR1002097B (en) 1995-12-28

Family

ID=23709269

Family Applications (1)

Application Number Title Priority Date Filing Date
GR900100786A GR1002097B (en) 1989-11-02 1990-11-01 A process for providing a composition an analgesic in combination with a h1 or h2 receptor blocker proto n pump ihibitor or combination thereof

Country Status (14)

Country Link
EP (1) EP0426479B1 (el)
JP (1) JPH03206052A (el)
KR (1) KR910009254A (el)
AT (1) ATE101515T1 (el)
AU (1) AU646230B2 (el)
CA (1) CA2028746C (el)
DE (1) DE69006684T2 (el)
ES (1) ES2057439T3 (el)
GR (1) GR1002097B (el)
IE (1) IE64953B1 (el)
IN (1) IN171746B (el)
NZ (1) NZ235877A (el)
PT (1) PT95753A (el)
ZA (1) ZA908775B (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69228738D1 (de) * 1991-12-06 1999-04-29 Glaxo Group Ltd Zusammensetzungen zur Behandlung von entzündlichen Zuständen oder Analgesie, die Ranitidin Wismuth Citrat und einen NSAID enthalten
WO1994007541A1 (en) * 1992-09-29 1994-04-14 Merck & Co., Inc. Ibuprofen-h2 antagonist combinations
GB9221414D0 (en) * 1992-10-13 1992-11-25 Glaxo Group Ltd Pharmaceutical compositions
US5648355A (en) * 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
ZA975444B (en) * 1996-06-20 1998-12-21 Mcneil Ppc Inc Acetaminophen and meclizine hydrochloride analgesics
WO1998058637A1 (en) * 1996-06-20 1998-12-30 Mcneil-Ppc Acetaminophen and diphenhydramine analgesics
DE19801811B4 (de) * 1998-01-19 2004-12-23 Stada Arzneimittel Ag Pharmazeutische Zubereitung zur oralen Verabreichung
US20050220909A1 (en) 2004-03-30 2005-10-06 Theoharides Theoharis C Composition for protection against superficial vasodilator flush syndrome
US7906153B2 (en) 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US7799766B2 (en) 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
GB9911017D0 (en) * 1999-05-13 1999-07-14 Zeneca Ltd Pharmaceutical compositions
IL145220A0 (en) * 1999-05-20 2002-06-30 Par Pharmaceutical Inc Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process
AU4973800A (en) * 1999-06-09 2000-12-28 Eli Lilly And Company Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
BR0207762A (pt) * 2001-03-08 2004-06-01 Astrazeneca Ab Uso de um composto ou um sal farmaceuticamente aceitável do mesmo, combinação, formulação farmacêutica, kit, método para a prevenção da úlcera gástrica induzida por medicamento, e, composição farmacêutica oral
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EA006398B1 (ru) 2001-06-01 2005-12-29 Поузен Инк. Фармацевтические композиции для координированной доставки нестероидных противовоспалительных лекарственных средств
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040185032A1 (en) * 2003-03-18 2004-09-23 David Burrell Compositions and methods for treating colic
US7923043B2 (en) 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
US7776873B2 (en) * 2005-12-01 2010-08-17 Yuhan Corporation Method for treating damage to gastric mucosa
CA2930063C (en) * 2008-01-04 2017-01-31 Schabar Research Associates Llc Unit oral solid dose compositions composed of naproxen sodium and nizatidine
MX2011002515A (es) 2008-09-09 2011-04-07 Astrazeneca Ab Metodo de administracion de una composicion farmaceutica a un paciente que lo necesita.
WO2010151216A1 (en) 2009-06-25 2010-12-29 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
US9050275B2 (en) 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
US9176146B2 (en) 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
CA3124579A1 (en) 2020-07-15 2022-01-15 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
IL299845A (en) 2020-07-15 2023-03-01 Schabar Res Associates Llc Oral unit dose compounds consisting of ibuprofen and famotidine for the treatment of acute pain and to reduce the severity and/or risk of heartburn

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1398A (en) * 1981-09-04 1987-12-18 Glaxo Group Ltd Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
US4522826A (en) * 1984-02-08 1985-06-11 Richardson-Vicks Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4757060A (en) * 1986-03-04 1988-07-12 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers

Also Published As

Publication number Publication date
PT95753A (pt) 1991-09-30
IE903946A1 (en) 1991-05-08
IN171746B (el) 1992-12-26
ES2057439T3 (es) 1994-10-16
DE69006684D1 (de) 1994-03-24
AU646230B2 (en) 1994-02-17
CA2028746A1 (en) 1991-05-03
ZA908775B (en) 1992-07-29
EP0426479A1 (en) 1991-05-08
AU6568990A (en) 1991-05-09
GR900100786A (el) 1992-04-17
DE69006684T2 (de) 1994-06-09
EP0426479B1 (en) 1994-02-16
NZ235877A (en) 1992-09-25
CA2028746C (en) 1995-12-26
ATE101515T1 (de) 1994-03-15
JPH03206052A (ja) 1991-09-09
IE64953B1 (en) 1995-09-20
KR910009254A (ko) 1991-06-28

Similar Documents

Publication Publication Date Title
GR1002097B (en) A process for providing a composition an analgesic in combination with a h1 or h2 receptor blocker proto n pump ihibitor or combination thereof
IL76932A (en) Synergistic pharmaceutical analgesic compositions containing dihydrocodeine and ibuprofen
GEP20002013B (en) Therapeutical Means
NO924169D0 (no) Preparat omfattende et tramadolmateriale og et ikke-stereoid antiinflammatorisk legemiddel
DK1024815T3 (da) Farmaceutisk sammensætning til oral administrering af molekylært iod
BE901667A (fr) Composition analgesique et anti-inflammatoire a base de diphenhydramine, leur preparation et leur utilisation.
NO20053104D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse for administrering ±n gang pr. dag.
ATE169498T1 (de) Zusammensetzung, die eine tramadol-verbindung und acetaminophen enthält, und ihre verwendung
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
EP1003494A4 (en) (d) -METHADONE, NON-OPIOID ANALGESIC
NO992468L (no) Sammensetning for behandling av gastrointestinale forstyrrelser inneholdende vismut og NSAID
IL109076A0 (en) Imidazolo-quinoxalinones, their preparation and pharmaceutical compositions containing them
ATE240097T1 (de) Pharmaceutische zusammensetzung enthaltend (+)- ephedrin und einen h1 rezeptor antagonisten
EP0345883A3 (en) Use of dapiprazole for the manufacture of a pharmaceutical composition inhibiting the development of tolerance in the analgesic treatment with morphine
IL70407A (en) Synergistic analgesic pharmaceutical compositions in unit dosage form,comprising an analgesic agent and hydroxyzine
DK0911038T3 (da) Vandfri sammensætning omfattende lactulose
DE3879489D1 (de) Pharmazeutische kompositionen zum behandeln von adrenoleukodystrophie.
CA2090234A1 (en) Method for providing improved analgesic effect
ZA989356B (en) Pharmaceutical preparations
SE8504612L (sv) Analgetiska och antiinflammatoriska kompositioner innefattande difenhydramin och forfaranden for anvendning av dessa
BR9908155A (pt) Composto, composição farmacêutica, uso do composto, e, processo para intensificar cognição em um sujeito sofrendo de cognição diminuìda
BG100965A (en) New therapeutical injection-type analgetic pharmaceutical composition containing nimesulid (4-nitro, 2-phenoxyphenylmetanesulphonamide) for intramuscular administration and method for its preparation
HUP9903183A2 (hu) Olanzapin alkalmazása fájdalomcsillapító hatású gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees